# Advancements in metastatic cancer clinical trials > Developing situation record from CLSTR: https://clstr.news/situations/advancements-in-metastatic-cancer-clinical-trials > Updated: 2026-11-04T18:10:50.000Z. Sources: 26. Developments: 5. Recent phase 3 clinical trials have demonstrated significant survival benefits for various metastatic cancer treatments. In gastroesophageal adenocarcinoma, the HERIZON-GEA-01 trial showed that zanidatamab combined with chemotherapy reduced the risk of death by 24% compared to trastuzumab plus chemotherapy for HER2-positive patients. Researchers noted that adding tislelizumab may provide additional survival benefits, though this requires further evaluation. In the field of metastatic triple-negative breast cancer (TNBC), experts are evaluating antibody-drug conjugates (ADCs). The FDA has approved sacituzumab govitecan as a first-line option, both as a monotherapy and in combination with pembrolizumab, while datopotamab deruxtecan has emerged as a significant option based on the TROPION-Breast02 trial. Additionally, phase 2 trials of the bispecific antibody pumitamig showed antitumor activity in TNBC, including potential efficacy in cases with brain metastases. Regarding lung cancer, the DeLLphi-305 Phase III trial found that combining tarlatamab with durvalumab reduced the risk of death by 58% in small cell lung cancer (SCLC). In the OptiTROP-Lung06 trial, sacituzumab tirumotecan (sac-TMT) combined with Keytruda reduced the risk of disease progression or death by 51% in PD-L1-negative non-small cell lung cancer. Pumitamig also showed intracranial objective response rates of 38.2% in SCLC patients. In endometrial cancer, sac-TMT—which targets the TROP2 protein—showed a median overall survival of 19.0 months compared to 12.1 months for standard chemotherapy, representing a 32% reduction in the relative risk of death. However, grade 3 or higher treatment-related side effects occurred in 54.4% of the sac-TMT group. ## Timeline ### 2026-11-04: Clinical trials show improved outcomes for specific lung cancer treatments New clinical trial data show sac-TMT plus Keytruda improves progression-free survival in PD-L1-negative NSCLC, while pumitamig plus chemotherapy shows potential intracranial activity in SCLC and TNBC. 2 sources. https://clstr.news/cluster/clinical-trials-show-improved-outcomes-for-specific-lung-cancer-treatments ### 2026-10-28: Sacituzumab tirumotecan improves survival in advanced endometrial cancer trial A phase 3 trial shows sacituzumab tirumotecan extends median overall survival to 19 months in patients with advanced endometrial cancer, compared to 12.1 months with standard chemotherapy. 4 sources. https://clstr.news/cluster/sacituzumab-tirumotecan-improves-survival-in-advanced-endometrial-cancer-trial ### 2026-10-28: New clinical trials show progress in endometrial and ovarian cancer treatments Clinical trials report breakthroughs in cancer treatment, including a drug reducing endometrial cancer death risk by 32% and a personalized NeoVax vaccine for ovarian cancer. 2 sources. https://clstr.news/cluster/new-clinical-trials-show-progress-in-endometrial-and-ovarian-cancer-treatments ### 2026-10-25: Oncology clinical trials show survival improvements across multiple cancer types New Phase III trial data presented at ESMO 2026 show significant survival benefits for small cell lung, biliary tract, and endometrial cancers using novel immunotherapy combinations. 19 sources. https://clstr.news/cluster/new-cancer-therapies-show-survival-benefits-in-phase-3-clinical-trials ### 2026-10-23: Clinical trials show progress in metastatic cancer treatments New clinical data shows zanidatamab improves survival in HER2-positive gastroesophageal cancer, while experts evaluate new ADC treatments for metastatic triple-negative breast cancer. 2 sources. https://clstr.news/cluster/clinical-trials-show-progress-in-metastatic-cancer-treatments --- Cite as: Advancements in metastatic cancer clinical trials. CLSTR, https://clstr.news/situations/advancements-in-metastatic-cancer-clinical-trials